IBM software offers affordable e-pedigree regulation compliance

6 May 2009

Global computing firm IBM and California, USA-based contract manufacturer and logistics provider Golden State Medical Supply have  partnered to help drugmakers comply with prescription drug pedigree  regulations ahead of Californian legislation that has been postponed to  2015. The biggest US state has pioneered rules to protect against  counterfeit drugs which are also being considered in other jurisdictions  (Marketletters passim).

The WebSphere Premises Server software overcomes many of the previous  obstacles to electronic pedigree programs faced by small- to mid-size  pharmaceutical companies, IBM claims. "New improvements in technology,  lower costs, as well as new industry standards for sharing and analyzing  information are making it possible for drug companies of any size to  ensure their drugs are authentic - while enabling the use of smart  technology to track movement of drugs from the manufacturing floor to  the pharmacy," the firm said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight